3 research outputs found

    EFFECTS OF AGEING ON GAIT COMPLEXITY

    Get PDF
    Ageing alters gait patterns that influences the control mechanism of human movement. The aim of this study was to identify the age-related differences in complexity of gait kinematics. Gait is a fundamental but complex action, and loss of complexity has been suggested with ageing. In this study multiscale entropy (MSE) analysis was used to investigate complexity in gait. Whole body kinematic data for 10 younger adults (21±1.84 years old) and 10 older adults (62.7±2.2 years old) running at 9 km/h on the treadmill for 2 minutes were analysed. Body centre of mass (CoM) were calculated. MSE of CoM position, and ankle, knee and hip angles were estimated. Hip angular displacement exhibited higher MSE (higher complexity) compared to the CoM position, ankle and knee angular displacement. MSE increased from ankle to knee to hip. MSE of the Hip was significantly lower for the older compared to the younger group, but MSE was not different between young and old participants for other variables. Loss of complexity may only be observed for some kinematic variables, which is a key point to consider for future work applying these techniques to understand gait changes with age

    Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

    Get PDF
    Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments in patients hospitalised for COVID-19 (NCT04381936, ISRCTN50189673). In this assessment of DMF performed at 27 UK hospitals, adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus DMF. The primary outcome was clinical status on day 5 measured on a seven-point ordinal scale. Secondary outcomes were time to sustained improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day 5 C-reactive protein, and improvement in day 10 clinical status. Between 2 March 2021 and 18 November 2021, 713 patients were enroled in the DMF evaluation, of whom 356 were randomly allocated to receive usual care plus DMF, and 357 to usual care alone. 95% of patients received corticosteroids as part of routine care. There was no evidence of a beneficial effect of DMF on clinical status at day 5 (common odds ratio of unfavourable outcome 1.12; 95% CI 0.86-1.47; p = 0.40). There was no significant effect of DMF on any secondary outcome

    Bioimaging In Vivo to Discern the Evolution of Late Effects Temporally and Spatially

    No full text
    corecore